Patent Holder Sues Regeneron & Pfizer & BioNTech Over Use of Proprietary ‘mNeonGreen’ Tech for COVID-19
Much attention has gone to Regeneron and the monoclonal antibody cocktail known as REGN-CoV2, especially given the investigational drug was […]
Much attention has gone to Regeneron and the monoclonal antibody cocktail known as REGN-CoV2, especially given the investigational drug was […]
The COVID-19 vaccine candidate known as BNT162b2 may be getting closer to registration (e.g. approval) as the European Medicines Agency […]
Pfizer’s CEO Albert Bourla joined Martha Brennan with CBS Face the Nation. An interesting character, he’s not just the standard […]
Daina Graybosch, a top life science research analyst at SVB Leerink covering Immuno-Oncology, recently communicated to investors that Pfizer and partner […]
Thanks to a partnership with J Lewis Research, healthcare provider Foothill Family Clinic in Salt Lake City, Utah, is conducting two Phase […]
TrialSite recently reported on privately-held Aventiv Research Inc. as the only trial site organization in this part of Central Ohio to […]
“Project Lightspeed” is coming to University Hospitals Cleveland Medical Center (UH) to conduct the pivotal Phase 2/3 global clinical trial […]
The Project Lightspeed initiative has come to Nashville, Tennessee. Clinical Research Associates, a trial site organization was selected by Pfizer to […]
New Haven, Connecticut, like many American cities, represents a multiplicity of reality exemplifying economic, social, cultural, and demographic diversity—that can […]
Independently-owned Columbus Ohio-based Aventiv Research was selected by the Pfizer/BioNTech “Project Lightspeed” program to participate in the Phase 2/3 clincial […]